Ring Out the False and Ring in the True: Our Last Episode of 2010
Host: Michael Greenberg, MD and Matthew Birnholz, MD
Guest: Everett Winslow Lovrien, MD
This week, hosts Drs. Matt Birnholz and Michael Greenberg wrap up 2010 with a look at the year's most notable research; as well as some notably retracted research, with Jef Akst of The Scientist; and talk wi…
Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities
At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—will be much discussed. In this curtain raiser, BioSpace speaks with conference chair Prathap Nagaraja Shastri of J&J about these highly anticipated topics.…
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
This week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year’s BIO Conference in Boston. The half-team discusses this week’s biggest news: the death of another patient who took Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys.
The patient was a non-am…
FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap
Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot button issues ranging from his recent overhaul over the CDC’s Advisory Committee on Immunization Practices (ACIP) committee, Kennedy’s recently publ…
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung, professor and chair at Johns Hopkins Bloomberg School of Public Health, these policy shifts are an “overdue adaptation to scientific progress.”
In …
FDA Chaos and Foreign Price Controls Are Collapsing American Innovation
FDA reversals and price controls are handing biotech dominance to China. We expose the national security crisis in drug development.The FDA is facing a crisis of confidence that threatens the stability of the entire US biopharmaceutical industry. In this episode, John Stanford is joined by Jef Akst…
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorizatio…
The FDA Decoded: Roles, Responsibilities & What They Mean for Drug Development
What does the FDA actually look like on the inside — and why does its structure matter for drug approvals, rare disease therapies, and biotech investment?This week on the Making Medicine Podcast, host John Stanford is joined by Jef Akst, senior editor at BioSpace, to break down the FDA's key divisi…
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, scooping up Apogee Therapeutics and its IL-23 blocker for atopic dermatitis for a…
Bonus: Q2 2026 Job Market Update
In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
MOTOR DE PESQUISA DE PODCAST
Pode usar nosso site para pesquisar podcasts3,821,933e episódios195,425,708por pessoas, lugares ou tópicos.
Investir em conhecimento rende os melhores juros; por isso, ouço podcasts.
‐ Benjamin "Llamacorn" Franklin
EDITAR
Obrigado por ajudar a manter a base de dados dos podcasts atualizada.
